115c26186ba53bf3b0a888b94f2bc96f

ABSOLUTE PRO PERIPHERAL SELF-EXPANDING STENT SYSTEM/ SISTEMA DE STENT PERÍFÉRICO AUTOEXPANSIBLE

ABBOTT LABORATORIES DE COLOMBIA S.A.S.·IIb·Colombia INVIMA·Expires December 22, 2033
Device classification
Risk class / Clase de Riesgo
IIb
Product type (Spanish)
MEDICO QUIRURGICOS
Product type (English)
SURGICAL DOCTOR
Registration information
Analysis ID
115c26186ba53bf3b0a888b94f2bc96f
Expire date
December 22, 2033
Authorized company / Fabricante
Name (English)
ABBOTT LABORATORIES DE COLOMBIA S.A.S.
Product use / Uso del Producto
Spanish

EL SISTEMA DE STENT PERIFÉRICO AUTOEXPANSIBLE ESTÁ INDICADO PARA LA IMPLANTACIÓN DE STENTS EN LAS ARTERIAS PERIFÉRICAS COMO TÉCNICA COMPLEMENTARIA DE LA ANGIOPLASTIA TRANSLUMINAL PERCUTÁNEA (ATP) Y COMO TRATAMIENTO PALIATIVO DE ESTENOSIS CAUSADAS POR UNA NEOPLASIA MALIGNA EN EL ÁRBOL BILIAR.

English

THE SELF-EXPANDING PERIPHERAL STENT SYSTEM IS INDICATED FOR THE IMPLANTATION OF STENTS IN THE PERIPHERAL ARTERIES AS A COMPLEMENTARY TECHNIQUE TO PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) AND AS PALLIATIVE TREATMENT OF STENOSIS CAUSED BY A MALIGNANT NEOPLASM IN THE BILIARY TREE.

About this record

Access comprehensive regulatory information for ABSOLUTE PRO PERIPHERAL SELF-EXPANDING STENT SYSTEM/ SISTEMA DE STENT PERÍFÉRICO AUTOEXPANSIBLE (ABSOLUTE PRO PERIPHERAL SELF-EXPANDING STENT SYSTEM/ SISTEMA DE STENT PERÍFÉRICO AUTOEXPANSIBLE) in the Colombia medical device market through Pure Global AI's free database. This IIb medical device is registered under INVIMA analysis ID 115c26186ba53bf3b0a888b94f2bc96f and manufactured by ABBOTT LABORATORIES DE COLOMBIA S.A.S.. The device was registered on December 22, 2033.

This page provides complete registration details including product type (SURGICAL DOCTOR), authorised information, and regulatory compliance data from the official Colombia INVIMA medical device database. Pure Global AI offers free access to Colombia's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate INVIMA regulations efficiently.